| 3 | 1/1 | 返回列表 |
| 查看: 1117 | 回復(fù): 2 | |||
[交流]
美國猶他大學(xué)分子影像和生物材料方向招收全額獎(jiǎng)學(xué)金博士后以及博士研究生
|
|
美國猶他大學(xué)是美國猶他州的高等教育旗艦型大學(xué),也是一所世界頂尖的公立研究型大學(xué), 屬于北美頂級(jí)研究型大學(xué)聯(lián)盟美國大學(xué)協(xié)會(huì)(AAU)、太平洋十二校聯(lián)盟(PAC-12)成員,為特高研究型大學(xué)(Top-tier Research university)。2025U.S. News美國最佳公立大學(xué)排名第69位,2024WRWU世界大學(xué)排名第65位, 2024軟科世界大學(xué)學(xué)術(shù)排名第101-150, 可入學(xué)藥學(xué)院2025U.S. News美國專業(yè)排名全美第26位。 Dr. Shi共發(fā)表40余篇文章(引用>4735, H因子33),包括 ACS Nano, Angewandte Chemie, Biomaterials, JNM, Nature Nanotechnology等本領(lǐng)域頂級(jí)期刊。擔(dān)任Journal of Nanobiotechnology(IF=10.6)副主編,并獲得 SNMMI Ones to Watch 2020等諸多榮譽(yù)。本實(shí)驗(yàn)室學(xué)生/博士后大多都在第一年/第二年獲得了優(yōu)秀學(xué)生獎(jiǎng)學(xué)金、國際會(huì)議墻報(bào)獎(jiǎng)等優(yōu)異成績,期待新的學(xué)生/博士后加入繼續(xù)實(shí)驗(yàn)室的優(yōu)秀紀(jì)錄。 招生要求: 1. 分子影像、生物、化學(xué)、材料等相關(guān)背景的博士、碩士、本科最后一年應(yīng)屆生。 2. 學(xué)習(xí)成績優(yōu)異,有鉆研精神。有科研經(jīng)歷和論文發(fā)表者優(yōu)先。 3. 有良好的英文基礎(chǔ),達(dá)到托福80分或者雅思6.5分。 薪資待遇: 博士后:NIH工資和福利 博士研究生:全額獎(jiǎng)學(xué)金(RA) 有意者請(qǐng)聯(lián)系sixiang.shi@utah.edu 實(shí)驗(yàn)室網(wǎng)址:https://www.miniresearchlabs.net/ 具體招生信息如下: Open Positions at the MINILabs at University of Utah -- PI Dr. Sixiang Shi The Molecular Imaging and Nanotechnology Innovation Laboratory (MINILabs) is seeking graduate students, postdoctoral fellows, and visiting scholars to lead research efforts at the intersection of molecular imaging and nanomedicine. Our core mission is to revolutionize the way we visualize, understand and treat cancer and other diseases, by potentiating simple but powerful solutions to biomedical and healthcare challenges. Laboratory Research Directions: 1. Application of advanced molecular imaging techniques (PET/CT, optics, optoacoustic imaging, etc.) in cancer, regenerative medicine and other diseases; 2. Development of innovative nanomedicine and natural biomaterials for personalized theranostics; 3. Development of novel radiochemistry and targeted radiotherapy for refractory diseases; 4. Utilizing advanced imaging tools to understand the biological unknowns in tumor microenvironment, metastasis, immunology, etc. Trainees will be a part of a highly multidisciplinary and collaborative group within the Department of Radiology and Imaging Sciences and the Department of Molecular Pharmaceutics at the University of Utah, led jointly by PIs Dr. Shi and Dr. Goel. The excellent academic environment at the University of Utah offers excellent career development and enhancement opportunities at all levels. Applicant Requirements: 1. Familiarity with advanced techniques in molecular biology, biomedical imaging and biomaterials research is preferred. 2. Successful candidates will be motivated, curious and independent thinkers with a strong sense of responsibility and good oral and written communication skills. 3. Applicants should be final-year PhD/masters/4th-year undergraduate students. 4. The students exhibiting outstanding performance with excellent GPA and research track record will be given preference. 5. The international students must successfully complete the English Proficiency Test (TOEFL 80 or IELTS 6.5). 6. Applicants for postdoctoral fellows with outstanding publication record and ability to work independently will be given priority. Contact: Interested candidates are recommended to send their CVs to Dr. Sixiang Shi (sixiang.shi@utah.edu). Principal Investigator (PI): Dr. Sixiang Shi received his PhD degree in Materials Science and Engineering from the University of Wisconsin-Madison in 2016 and completed his postdoctoral fellowship from MD Anderson Cancer Center in 2020. He shortly worked in the Department of Health Technology and Informatics at the Hong Kong Polytechnic University as an Assistant Professor in 2021. He joined the Department of Radiology and Imaging Sciences at the University of Utah in August 2022. So far, he has published >40 papers (>4735 citations, h-index: 33), in top journals such as ACS Nano, Angewandte Chemie, Biomaterials, JNM, Nature Nanotechnology, among others. Dr. Shi serves as Associate Editor for Journal of Nanobiotechnology, Editorial Member for Journal of Functional Biomaterials, and reviewer for more than 20 journals, scientific societies, grants agencies and conferences. Dr. Shi has received multiple awards and honors for his research and scholarship, including the SNMMI Ones to Watch 2020, which recognizes most promising researchers worldwide in the fields of nuclear medicine and molecular imaging. Details can be found via https://www.miniresearchlabs.net/ |
» 搶金幣啦!回帖就可以得到:
+2/104
+1/85
+2/46
+1/35
+2/34
+1/33
+1/33
+1/32
+1/13
+1/13
+1/10
+1/8
+1/8
+1/7
+1/5
+1/5
+1/5
+1/2
+1/2
+1/1
超級(jí)版主 (文學(xué)泰斗)
| 3 | 1/1 | 返回列表 |
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 化學(xué) 0703求調(diào)劑 總分293 一志愿211 +8 | 土土小蟲 2026-03-03 | 10/500 |
|
|---|---|---|---|---|
|
[考研] 材料與化工,291分,求調(diào)劑 +8 | 咕嚕咕嚕123123 2026-03-04 | 10/500 |
|
|
[考研] 302材料工程求調(diào)劑 +6 | Doleres 2026-03-01 | 7/350 |
|
|
[考研] 學(xué)碩材料275調(diào)劑 +9 | 路三三 2026-03-03 | 9/450 |
|
|
[考研] 材料化工調(diào)劑 +15 | 今夏不夏 2026-03-01 | 18/900 |
|
|
[考研]
085600 英一數(shù)二272求調(diào)劑
5+6
|
vida_a 2026-03-01 | 47/2350 |
|
|
[考研] 085601 材料305分求助 +4 | 泡泡郵件 2026-03-03 | 6/300 |
|
|
[考博] 26申博-目前4篇SCI一作 +3 | chen_2024 2026-03-02 | 3/150 |
|
|
[考研] 一志愿西工大材料學(xué),英一數(shù)二總分321分,求調(diào)劑。 +3 | zz05zz 2026-03-02 | 5/250 |
|
|
[考研] 中國林科院林化所(南京)2026年招收化學(xué)/材料/環(huán)境工程等背景碩士研究生3名 +3 | realstar2006 2026-02-27 | 3/150 |
|
|
[基金申請(qǐng)] 請(qǐng)問大家,研究風(fēng)險(xiǎn)與應(yīng)對(duì)措施那里, 大家都怎么寫呢 ? +3 | cauasen 2026-03-02 | 3/150 |
|
|
[考研] 284求調(diào)劑 +6 | 天下熯 2026-03-02 | 6/300 |
|
|
[考研] 化學(xué)0703求調(diào)劑 學(xué)碩 理/工科均可 總分279 +3 | 1一11 2026-03-03 | 5/250 |
|
|
[考研] 沒上岸的看過來 +3 | tangxiaotian 2026-03-01 | 3/150 |
|
|
[考研] 298求調(diào)劑 +7 | axyz3 2026-02-28 | 8/400 |
|
|
[考研] 一志愿山東大學(xué)材料與化工325求調(diào)劑 +5 | 半截的詩0927 2026-03-02 | 5/250 |
|
|
[考研] 272求調(diào)劑 +6 | 田智友 2026-02-28 | 6/300 |
|
|
[考研] 290求調(diào)劑 +9 | 材料專碩調(diào)劑; 2026-02-28 | 11/550 |
|
|
[考研] 295復(fù)試調(diào)劑 +3 | 簡木ChuFront 2026-03-01 | 3/150 |
|
|
[考研] 317一志愿華南理工電氣工程求調(diào)劑 +6 | Soliloquy_Q 2026-02-28 | 11/550 |
|